GLE1

Across TCGA pan-cancer cohorts, GLE1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GLE1 data layer compared with 22 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher GLE1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated GLE1 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where GLE1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.395	0.658	<.001	81	view →
LUAD	OS	Median	II,III,IV	1.000	0.862	.004	39	view →
CCRCC	OS	Median	All	0.885	1.000	.002	36	view →
LSCC	OS	Quartile	All	0.901	0.596	.010	10	view →
UCEC	DFS	Tertile	III,IV	1.000	0.352	.042	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GLE1–PDAC (OS)

Open the PDAC breakdown →